

Curriculum Vitae

Name, first name, title	Jaime Kulisevsky, MD, PhD
Hospital or office address	Sant Pau Hospital (Autonomous University of Barcelona)
	Institut de Recerca
	Av. Sant Antoni M. Claret 167
	Pavelló Sant Frederic, 1ª Planta
	08025 Barcelona - Spain
	Phone: +34 93 553 76 13
	Fax: +34 93 553 78 72

	Date (dd.mm.yyyy)	Place
Date and place of birth	14 May 1956	Salta, Argentina
Nationality		Spanish
Medical license acquired (Approbation)	1981	Medicine

	from (year)	Field
Specialist in PhD	1986	Neurology (Spanish National Health System)
	1992	Autonomous University of Barcelona

PROFESSIONAL CAREER	from (year)	to (year)	Place
Residence in Neurology	1982	1985	Hospital Sant Pau, Barcelona
Neurologist	1986	1987	Hospital Clinic, Barcelona
Neurologist	1988	1989	Hospital Trias i Pujol, Barcelona
Neurologist	1989	1996	Sant Pau Hospital, Barcelona
Clinical Chief	1996	2003	Hospital Sant Pau, Barcelona
Director, Movement Disorders Unit	1996	present	Sant Pau Hospital, Barcelona
Director of the Research Institute of Sant Pau Hospital	2008	present	Sant Pau Hospital, Barcelona

Publications	yes <input checked="" type="checkbox"/>	no
---------------------	---	----

ACADEMIC POSITIONS	from (year)	to (year)	Place
---------------------------	-----------------------	---------------------	--------------

Coordinator, Master in Neuropsychological Diagnosis and Rehabilitation	1999	present	Autonomous University of Barcelona
Associate Professor	2009	present	Autonomous University of Barcelona
Associate Professor	2014	present	Universitat Oberta de Catalunya
Associate Dean	2017	present	Autonomous University of Barcelona

SCIENTIFIC SOCIETIES

- Spanish Society of Neurology (SEN)
- Member of the Movement Disorders Study Group (SEN)
- Member of the Dementia and Behaviour Study Group (SEN)
- Member of the Aphasiology and Behavioural Neurology Group of the World federation of Neurology
- Catalan Society of Neurology (SCN)
- Movement Disorder Society
- American Academy of Neurology
- European Neurological Society
- Member of the European Huntington Disease Network (EHDN)
- Corresponding Member of the Royal Academy of Medicine and Surgery in Murcia, Spain

ACADEMIC WORK

- Vocal of the Study Group on Movement Disorders Spanish Neurological Society (SEN) 1992-1994 y 1996-1998)
- Coordinator of the Movement Disorders Study Group (SEN 1998-2000)
- Member of the SEN Teaching Committee (2000-2002)
- Member of the Committee "Aphasiology and Behavioral Neurology of the World Federation of Neurology" (2000-2002)
- Member of Scientific and Accreditation Committee - SEN (2003-2005)
- Ad Hoc Committee Member of Neurology in Training - SEN (2003-2005)
- Coordinator of the "Clinical Practice Guidelines on Parkinson's Disease". SEN Study Group on Movement Disorders (1998-1999).
- Advisory Member of the SCN for the Neurological Diseases Protocols: Parkinson Disease (1997-2000).
- Member of the Panel of Evaluators of the General Department of Health Research (2000-to date).
- Member of the Panel of Examiners for Biomedical and Health Sciences, National Evaluation and Foresight (ANEP) (2002-to date).
- Member of the Committee on Development of the "Protocol guided use of non-drug treatments for Parkinson's Disease." Agency for Health Technology Assessment Health Institute "Carlos III" (2000-to date).

- Member of the Committee of Assessors of the Health Research Fund (FIS), Ministry of Health. (Health Research Fund - Instituto Carlos III) (2002-to date)
- Member of the Subcommittee on Rare Neurological Diseases, of the Spanish Society of Neurology (2008-2012)
- Member of the Investigation Committee of the Barcelona Metropolitan Strategic Plan (2010-2014)
- Member of the Medical Advisor to the TV3 Marathon Foundation (2008-to present)
- Member of the board of CIBER (BIOMEDICAL RESEARCH CENTER NETWORK, Cibered on Neurological Diseases, Ciberer on Rare Diseases, Cibersam on Mental Health, Ciberbbn on Bioengineering, Biomaterials and Nanomedicine, Ciberdem on Diabetes and Associated Metabolic Disorders, Ciberehd on Liver and Digestive Diseases and Ciberesp on Epidemiology and Public Health) 2008-to date.
- Coordinator of the Clinical Practice Guide on the comprehensive approach on care of people with Alzheimer's disease and other dementias from 2010 (<http://aunets.isciii.es/web/guest/home>)
- Member of the information agency, evaluation and quality in health (AIAQS)
- Member of the International Movement Disorders Society Task Force for Developing Rating Scales in Parkinson's disease -UPDRS- (Subcommittee for Cognitive Evaluation) (2005-to date)
- Member of the Executive Committee of the Movement Disorders Society (European Section) (2007-to date)
- Member of the 'Education in Europe Working Group' of the Movement Disorders Society (2007- 2011)
- Reviewer of International Research Projects: Peer Reviewers for Themed Grants for different countries (Netherlands, Israel)
- Member of the EFNS/MDS-ES (European Federation of Neurological Societies / Movement Disorders Society – European Section) Task Force Project on Diagnosis of Parkinson's Disease from 2010-2014
- Advisory Member at the Michael J. Fox Foundation (2011- 2013)
- Member of the Movement Disorders Society (MDS) Evidence Based Medicine (EBM) Committee Huntington's Disease Subgroup (2015-to date)
- Advisory Board on IONIS ASO HTT Rx for Huntington's Disease (HD)

RESEARCH GRANTS AWARDED (IN THE LAST 5 YEARS)

- "Development of experimental animal models in PD". CIBERNED (2012)
J. Kulisevsky
- "Extension study validation and sensitivity to change of an alternative version of the Parkinson's Disease Cognitive Rating Scale". Centro de Investigaciones Biomédicas en Red (CIBER) Neurodegenerative Diseases (CIBERNED). Spanish Health Institute Carlos III (2012)
- "Prediction of apathy and impulse control disorder in Parkinson's disease based on feedback related negativity". Fundació La Marató de TV3 (2015)
J. Kulisevsky
- "Blood and neurophysiological levels in progression of cognitive impairment in Parkinson's disease". Ministerio de Economía y Competitividad (2015)

J. Kulisevsky

- “Longitudinal Study of neuroradiologic and clinic correlates associate with huntingtin levels and other CSF and plasma biomarkers in Huntington’s Disease”. Health Research Found (FIS), Spanish Ministry of Health. Reference: FIS PI17/01885 (2017)

RESEARCH PROJECTS (NATIONAL AND/OR INTERNATIONAL IN THE LAST 5 YEARS)

- “Study the effects of training using Think Neurofeedback system (NFBT) in patients with Attention Deficit Hyperactive Disorders (ADHD)”. Think Interfaces Incorporated (2012)
J. Kulisevsky
- “Monocentric randomized, double-blind, controlled study of the effects of neurofeedback over executive functions deficits and reaction time in ADHD: A neuropsychological and functional magnetic resonance imaging study”. Think Interfaces Incorporated (2012)
J. Kulisevsky
- “Observational, retrospective, multicenter study to evaluate the effectiveness of Levodopa/carbidopa intestinal gel infusion in patients with advanced disease Parkinson”. Abbott Laboratories, S.A. (2012).
J. Kulisevsky
- “Double-blind, placebo-controlled, fixed-dose, multicenter, 13-week follow-up to evaluate the efficacy and safety of modified release AFQ056 in reducing levodopa-induced dyskinesias, moderate to severe”. Novartis Farmacéutica, S.A. (2012)
J. Kulisevsky
- “Open study to assess the safety, tolerability and efficacy of AFQ056 in levodopa-induced dyskinesia in patients with Parkinson's”. Novartis Farmacéutica, S.A. (2012).
J. Kulisevsky
- “Phase IV multicenter, double-blind, placebo-controlled, parallel-group study to assess the effect of rotigotine on non-motor symptoms in patients with idiopathic Parkinson disease test”. PRA INTERNACIONAL. (2012).
J. Kulisevsky
- “Gabapentin in the impulse control disorder Parkinson's disease: multicentre, double-blind, randomized, placebo-controlled study”. Asociacion Instituto Bionostia. (2013).
J. Kulisevsky
- “Multicenter, multinational, double-blind, placebo-controlled, three-arm phase 4, to evaluate the effectiveness of rotigotine in the study apathy, motor symptoms and mood swings associated with Parkinson's disease, Bright Phase 4”. UCB Pharma, S.A. (2013)
J. Kulisevsky
- “Extension study of Phase 3, 40-week, active-controlled, double-blind and double simulation preladenant in subjects with Parkinson's disease of moderate to severe ". Schering-Plough, S.A. (2013)
J. Kulisevsky
- “Multicenter, randomized, double-blind, placebo-controlled 26-week duration, to evaluate the effectiveness and safety of amantadine hydrochloride, extended-release tablets in patients with

Parkinson's disease with levodopa-induced dyskinesias". OSMOTICA PHARMACEUTICAL CORP. (2014)

J. Kulisevsky

- "Multicenter, multinational, randomized, double-blind, placebo-controlled parallel group, in which the efficacy and safety of treatment with laquinimod is evaluated (0,5,1,0 and 1.5 mg / day) in patients with disease study Huntington". TEVA. (2014).

J. Kulisevsky 

- Open study to assess the safety, tolerability and efficacy of AFQ056 in levodopa-induced dyskinesia in patients with Parkinson's treatment". Novartis. (2015).

J. Kulisevsky

- "Gabapentin in the impulse control disorder Parkinson's disease: multicentre, double-blind, randomized, placebo-controlled study". ASOCIACIÓN INSTITUTO BIODONOSTIA. (2015).

j. Kulisevsky

- "Randomized double-blind Think Interfaces® effects on memory and attention in patients with attention deficit disorder and hyperactivity (attentional type, hyperactive-impulsive type, combined type) and healthy control study. THINK INTERFACES INC. (2015).

J. Kulisevsky

- "Multicenter, randomized, double-blind, placebo-controlled study and 16 weeks to assess the effectiveness and safety of amantadine hydrochloride, extended-release tablets in patients with Parkinson's disease". OSMOTICA PHARMACEUTICAL CORP. (2015)

J. Kulisevsky

- COPPADIS-2015 COhort of Patients with PArkinson´s Disease in Spain, (2015)

Santos-Garcia

- "Randomized, double-blind crossover comparison of levodopa immediate-release (IR-LD) and intestinal gel L-dopa/carbidopa (LCIG) in cognition and mood in non-demented patients with Parkinson's disease (PD)". Abbvie Inc. (2015)

J. Kulisevsky

- A Phase 3, Multicenter, Randomizd, Double-Blind, Placebo-Controlled Study with an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson´s Disease Experiencing End-of-Dose "Wearing- Off". Biotie Therapies (2015).

J. Kulisevsky

- Prospective, Phase IIb/III, multicenter, randomized, double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of masitinib versus placebo in the treatment of patients with progressive supranuclear palsy (PSP)". AB Science (2015).

J. Kulisevsky

- Ensayo clínico aleatorizado, doble ciego y controlado por placebo, de evaluación de la eficacia y la seguridad del candesartán versus placebo en el deterioro cognitivo leve asociado a la enfermedad de Parkinson. Estudio exploratorio. IIBSP-CAN-2016-16 (2016)

J. Kulisevsky

- Estudio de sintomatología y medidas de salud autopercibidas en pacientes con infusión intestinal continua de levodopa/carbidopa, y sus cuidadores, para el tratamiento de la enfermedad de Parkinson avanzado. Estudio ADEQUA. (2016)
J. Kulisevsky
- Estudio en fase II de búsqueda de dosis, doble ciego, aleatorizado, controlado con placebo y de 15 semanas de duración para investigar la eficacia, la Seguridad y la tolerabilidad del PF-06649751 en sujetos con fluctuaciones motores por enfermedad de Parkinson. Pfizer Barcelona (2016).
J. Kulisevsky
- European multicenter retrospective-prospective cohort study to observe Safinamide safety profile and pattern of use in clinical practice during the first post-commercialization phase. Zambón. (2016).
- Ensayo clínico aleatorizado, doble ciego y controlado por placebo, de evaluación de la eficacia y la seguridad del candesartán versus placebo en el deterioro cognitivo leve asociado a la enfermedad de Parkinson. Estudio exploratorio. IIBSP-CAN-2016-16. (2016).
J. Kulisevsky
- Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia, seguridad, farmacocinética y farmacodinamia de GZ/SAR402671 en pacientes con Enfermedad de Parkinson en estadio inicial, portadores de la mutación GBA u otra variante pre-especificada. Genzyme Corporation. (2017)
J. Kulisevsky
- A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents. Teva Branded Pharmaceutical (2017).
J. Kulisevsky
- A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy. Bristol-Myers Squibb Research and Development. (2017)
J. Kulisevsky
- A Randomized, double-blind, placebo-controlled, 52-week phase II study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early parkinson´s disease with a 52-week blinded extensión (PASADENA). 2017-000087-15. F. Hoffmann-La Roche Ltd. (2017)
J. Kulisevsky
- “European multicenter retrospective-prospective cohort study to observe Safinamide safety profile and pattern of use in clinical practice during the first post-commercialization phase”.
Z7219N02. Zambon (2017)
J. Kulisevsky
- Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease FAIR-PARK-II. 2015-003679-31. (2017)

- Dose finding phase IIb study of Bavisant to evaluate its safety and efficacy in treatment of excessive daytime sleepiness (ESD) in Parkinson's Disease (PD). BEN01/BB-2001-201b. BenevolentAI Bio. (2018)
J. Kulisevsky
- Estudio descriptivo, con grupo control y unicéntrico sobre la eficacia de la estimulación magnética transcraneal repetitiva del córtex prefrontal dorsolateral izquierdo como tratamiento de síntomas cognitivos y conductuales en la enfermedad de Huntington.
IIBSP-TMS-2017-64. (2018)
J. Kulisevsky

PUBLICATIONS (peer reviewed OF THE LAST 5 YEARS)

1. Ribosa-Nogué R, Pagonabarraga J, Kulisevsky J. "Efficacy of trazodone in antipsychotic-induced akathisia resistant to conventional treatment". *Parkinsonism Relat Disord.* 2012 Apr 29.
2. Pagonabarraga J, Kulisevsky J. "Cognitive impairment and dementia in Parkinson's disease". *Neurobiol Dis.* 2012 Jun;46(3):590-6. Epub
3. Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Kulisevsky J, Murphy SA; TRA 2P-TIMI 50 Steering Committee and Investigators. "Vorapaxar in the secondary prevention of atherothrombotic events". *N Engl J Med.* 2012 Apr 12;366(15):1404-13.
4. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. "Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines". *Mov Disord.* 2012 Mar;27(3):349-56.
5. Setó-Salvia N, Pagonabarraga J, Houlden H, Pascual-Sedano B, Dols-Icardo O, Tucci A, Paisán-Ruiz C, Campolongo A, Antón-Aguirre S, Martín I, Muñoz L, Bufill E, Vilageliu L, Grinberg D, Cozar M, Blesa R, Lleó A, Hardy J, Kulisevsky J, Clarimón J. "Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course". *Mov Disord.* 2012 Mar;27(3):393-9.
6. Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. "Cognitive impairment in nondemented Parkinson's disease". *Mov Disord.* 2011 Dec;26(14):2483-95.
7. Kulisevsky J, Poyurovsky M. "Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders". *Eur Neurol.* 2012;67(1):4-11.
8. Martí MJ, Kulisevsky J. Candidate patient for treatment with continuous apomorphine infusion. *Rev Neurol.* 2012;55 Suppl 1:S15-9.
9. Pagonabarraga J, Gómez-Ansón B, Rotger R, Llebaria G, García-Sánchez C, Pascual-Sedano B, Gironell A, Delfino M, Rusalleda J, Kulisevsky J. Spectroscopic changes associated with mild cognitive impairment and dementia in Parkinson's disease. *Dement Geriatr Cogn Disord.* 2012;34(5-6):312-8.
10. Ribosa-Nogué R, Gironell A, Pagonabarraga J, Villa-Bonomo C, Pascual-Sedano B, Kulisevsky J. Descriptive analysis of the activity in a movement disorder unit in a tertiary hospital in Catalonia]. *Rev Neurol.* 2012 Sep 16;55(6):330-6.

11. Filippi M, Kulisevsky J. Advances with MRI in Parkinson disease: from freezing to festination. *Neurology*. 2012 Dec 4;79(23):2222-3..
12. Clarimón J, Kulisevsky J. Parkinson's disease: from genetics to clinical practice. *Curr Genomics*. 2013 Dec;14(8):560-7.
13. Pagonabarraga J, Corcuera-Solano I, Vives-Gilabert Y, Llebaria G, García-Sánchez C, Pascual-Sedano B, Delfino M, Kulisevsky J, Gómez-Ansón B. Pattern of regional cortical thinning associated with cognitive deterioration in Parkinson's disease. *PLoS One*. 2013;8(1):e54980.
14. Berardelli A, Wenning GK, Antonini A, Berg D, Bloem BR, Bonifati V, Brooks D, Burn DJ, Colosimo C, Fanciulli A, Ferreira J, Gasser T, Grandas F, Kanovsky P, Kostic V, Kulisevsky J, Oertel W, Poewe W, Reese JP, Relja M, Ruzicka E, Schrag A, Seppi K, Taba P, Vidailhet M. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. *Eur J Neurol*. 2013 Jan;20(1):16-34.
15. Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, de Bie RM, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Østergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzicka E, Samuel M, Speelman H, Sydow O, Valdeoriola F, van der Linden C, Oertel W. Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. *J Neurol*. 2013 Nov;260(11):2701-14.
16. Schapira AH, Stocchi F, Borgohain R, Onofri M, Bhatt M, Lorenzana P, Lucini V, Giuliani R, Anand R; Study 017 Investigators. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. *Eur J Neurol*. 2013 Feb;20(2):271-80.
17. Villa-Bonomo C, Pagonabarraga J, Martínez-Horta S, Fernández de Bobadilla R, García-Sánchez C, Campolongo A, Kulisevsky J. Short-lasting episodes of prosopagnosia in Parkinson's disease. *Parkinsonism Relat Disord*. 2013 Mar;19(3):375-7.
18. Martínez-Horta S, Pagonabarraga J, Fernández de Bobadilla R, García-Sánchez C, Kulisevsky J. Apathy in Parkinson's disease: more than just executive dysfunction. *J Int Neuropsychol Soc*. 2013 May;19(5):571-82.
19. Serrano-Munuera C, Corral-Juan M, Stevanin G, San Nicolás H, Roig C, Corral J, Campos B, de Jorge L, Morcillo-Suárez C, Navarro A, Forlani S, Durr A, Kulisevsky J, Brice A, Sánchez I, Volpini V, Matilla-Dueñas A. New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. *JAMA Neurol*. 2013 Jun;70(6):764-71.
20. Morales DA, Vives-Gilabert Y, Gómez-Ansón B, Bengoetxea E, Larrañaga P, Bielza C, Pagonabarraga J, Kulisevsky J, Corcuera-Solano I, Delfino M. Predicting dementia development in Parkinson's disease using Bayesian network classifiers. *Psychiatry Res*. 2013 Aug 30;213(2):92-8.
21. LeWitt PA, Boroojerdi B, Surmann E, Poewe W; SP716 Study Group; SP715 Study Group. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, {CLEOPATRA-PD} and {PREFER}. *J Neural Transm (Vienna)*. 2013 Jul;120(7):1069-81.
22. Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, Pascual-Sedano B, Campolongo A, Kulisevsky J. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. *Mov Disord*. 2013 Sep;28(10):1376-83.
23. Kulisevsky J, Fernández de Bobadilla R, Pagonabarraga J, Martínez-Horta S, Campolongo A, García-

- Sánchez C, Pascual-Sedano B, Ribosa-Nogué R, Villa-Bonomo C. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. *Parkinsonism Relat Disord*. 2013 Sep;19(9):812-7.
24. Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, Chacón J, García-Ruiz PJ, Lezcano E, Mir P, Martínez-Castrillo JC, Martínez-Torres I, Puente V, Sesar A, Valldeoriola-Serra F, Yañez R. Advanced Parkinson's disease: clinical characteristics and treatment (part 1). *Neurologia*. 2013 Oct;28(8):503-21.
25. Kurtis MM, Rodriguez-Blazquez C, Martínez-Martin P; ELEP Group. Relationship between sleep disorders and other non-motor symptoms in Parkinson's disease. *Parkinsonism Relat Disord*. 2013 Dec;19(12):1152-5.
26. Matias-Guiu JA, Fernández de Bobadilla R, Escudero G, Pérez-Pérez J, Cortés A, Morenas-Rodríguez E, Valles-Salgado M, Moreno-Ramos T, Kulisevsky J, Matías-Guiu J. Validation of the Spanish version of Addenbrooke's Cognitive Examination III for diagnosis dementia. *Neurologia*. 2015 Nov-Dec;30(9):545-51.
27. Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kiebertz K. Therapeutic development paths for cognitive impairment in Parkinson's Disease: report of a regulatory roundtable. *J Parkinsons Dis*. 2014;4(4):585-9.
28. Marras C, Tröster AI, Kulisevsky J, Stebbins GT. The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease. *Mov Disord*. 2014 Apr 15;29(5):584-96.
29. Martínez-Horta S, Riba J, de Bobadilla RF, Pagonabarraga J, Pascual-Sedano B, Antonijoan RM, Romero S, Mañanas MÀ, García-Sánchez C, Kulisevsky J. Apathy in Parkinson's disease: Neurophysiological evidence of impaired inceptive processing. *J Neurosci*. 2014 Apr 23;34(17):5918-26.
30. Cubo E, Doumbe J, Martínez-Martin P, Rodríguez-Blazquez C, Kuate C, Mariscal N, Lopez I, Noubissi G, Mapoure YN, Jon JL, Mbahe S, Tchaleu B, Catalan MJ; ELEP Group. Comparison of the clinical profile of Parkinson's disease between Spanish and Cameroonian cohorts. *J Neurol Sci*. 2014 Jan 15;336(1-2):122-6.
31. Pagonabarraga J, Kulisevsky J. Dopaminergic treatment in Parkinson's disease: what has each therapeutic family got to offer?. *Rev Neurol*. 2014 Jan 1;58(1):25-34.
32. Emre M, Poewe W, De Deyn PP, Barone P, Kulisevsky J, Pourcher E, van Laar T, Storch A, Micheli F, Burn D, Durif F, Pahwa R, Callegari F, Tenenbaum N, Strohmaier C. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. *Clin Neuropharmacol*. 2014 Jan-Feb;37(1):9-16.
33. Pagonabarraga J, Soriano-Mas C, Llebaria G, López-Solà M, Pujol J, Kulisevsky J. Neural correlates of minor hallucinations in non-demented patients with Parkinson's disease. *Parkinsonism Relat Disord*. 2014 Mar;20(3):290-6.
34. Tolosa E, Hernández B, Linazasoro G, López-Lozano JJ, Mir P, Marey J, Kulisevsky J. Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson's disease experiencing mild wearing-off: a randomised, double-blind trial. *J Neural Transm (Vienna)*. 2014 Apr;121(4):357-66.
35. Pagonabarraga J, Piñol G, Cardozo A, Sanz P, Puente V, Otermán P, Legarda I, Delgado T, Serrano

- C, Balaguer E, Aguirregomozcorta M, Álvarez R, Kulisevsky JJ. Transdermal Rotigotine improves sleep fragmentation in Parkinson's Disease: Results of the multicenter, prospective SLEEP-FRAM Study. *Parkinsons Dis.* 2015;2015:131508.
36. Riba J, Valle M, Sampedro F, Rodríguez-Pujadas A, Martínez-Horta S, Kulisevsky J, Rodríguez-Fornells A. Telling true from false: cannabis users show increased susceptibility to false memories. *Mol Psychiatry.* 2015 Jun;20(6):772-7.
 37. Spataro N, Calafell F, Cervera-Carles L, Casals F, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Kulisevsky J, Lleó A, Navarro A, Clarimón J, Bosch E. Mendelian genes for Parkinson's Disease contribute to the sporadic forms of the disease. *Hum Mol Genet.* 2015 Apr 1;24(7):2023-34.
 38. Pérez-Pérez J, Pagonabarraga J, Martínez-Horta S, Fernández-Bobadilla R, Sierra S, Pascual-Sedano B, Gironell A, Kulisevsky J. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. *Drugs Aging.* 2015 May;32(5):401-7.
 39. Krack P, Pagonabarraga J, Strafella AP, Kulisevsky J. Apathy: who cares?. *Lancet Neurol.* 2015 May;14(5):465.
 40. Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. *Lancet Neurol.* 2015 May;14(5):518-31.
 41. Gómez-Ansón B, Román E, Fernández de Bobadilla R, Pires-Encuentra P, Díaz-Manera J, Núñez F, Martínez-Horta S, Vives-Gilabert Y, Pagonabarraga J, Kulisevsky J, Cordoba J, Guarner C, Soriano G. Alterations in cerebral white matter and neuropsychology in patients with cirrhosis and falls. *PLoS One.* 2015 Mar 20;10(3):e0118930.
 42. Pérez-Pérez J, Martínez-Horta S, Pagonabarraga J, Carceller M, Kulisevsky J. Rasagiline for the treatment of parkinsonism in Huntington's disease. *Parkinsonism Relat Disord.* 2015 Mar;21(3):340-2.
 43. Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Martí MJ. Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry. *Parkinsonism Relat Disord.* 2015 Aug;21(8):871-6.
 44. Pagonabarraga J, Martínez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J, Pascual-Sedano B, García C, Gironell A, Kulisevsky J. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. *Mov Disord.* 2016 Jan;31(1):45-52.
 45. Martínez-Horta S, Pérez-Pérez J, van Duijn E, Fernández-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. *Parkinsonism Relat Disord.* 2016 Apr;25:58-64.
 46. Ruzafa-Valiente E, Fernández-Bobadilla R, García-Sánchez C, Pagonabarraga J, Martínez-Horta S, Kulisevsky J. Parkinson's Disease-Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment. *J Neurol Sci.* 2016 Feb 15;361:66-71.
 47. Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group. COPPADIS-2015 (COhort of Patients with PArkinson's

- Disease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. *BMC Neurol.* 2016 Feb 25;16(1):26.
48. Cervera-Carles L, Pagonabarraga J, Pascual-Sedano B, Pastor P, Campolongo A, Fortea J, Blesa R, Alcolea D, Morenas-Rodríguez E, Sala I, Lleó A, Kulisevsky J, Clarimón J. Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. *Am J Med Genet B Neuropsychiatr Genet.* 2016 Mar;171(2):175-80.
 49. Pastor P, Moreno F, Clarimón J, Ruiz A, Combarros O, Calero M, López de Munain A, Bullido MJ, de Pancorbo MM, Carro E, Antonell A, Coto E, Ortega-Cubero S, Hernandez I, Tárraga L, Boada M, Lleó A, Dols-Icardo O, Kulisevsky J, Vázquez-Higuera JL, Infante J, Rábano A, Fernández-Blázquez MÁ, Valentí M, Indakoetxea B, Barandiarán M, Gorostidi A, Frank-García A, Sastre I, Lorenzo E, Pastor MA, Elcoroaristizabal X, Lennarz M, Maier W, Rámirez A, Serrano-Ríos M, Lee SE, Sánchez-Juan P; Dementia Genetic Spanish Consortium (DEGESCO). MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOE ϵ 4 Noncarriers: Results from the Dementia Genetics Spanish Consortium. *J Alzheimers Dis.* 2016;49(2):343-52. doi: 10.3233/JAD-150555.
 50. Matías-Guiu JA, Fernández-Bobadilla R, Fernández-Oliveira A, Valles-Salgado M, Rognoni T, Cortés-Martínez A, Moreno-Ramos T, Kulisevsky J, Matías-Guiu J. Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III. *Dement Geriatr Cogn Disord.* 2016;41(5-6):243-50
 51. López-Mora DA, Camacho V, Pérez-Pérez J, Martínez-Horta S, Fernández A, Sampedro F, Montes A, Lozano-Martínez GA, Gómez-Anson B, Kulisevsky J, Carrió I. Striatal hypometabolism in premanifest and manifest Huntington's disease patients. *Eur J Nucl Med Mol Imaging.* 2016 Nov;43(12):2183-2189.
 52. Martínez-Horta S, Sampedro F, Pagonabarraga J, Fernandez-Bobadilla R, Marin-Lahoz J, Riba J, Kulisevsky J. Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. *Brain Imaging Behav.* 2017 Oct;11(5):1334-1342.
 53. Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. *JAMA Neurol.* 2017 Feb 1;74(2):216-224.
 54. Spataro N, Roca-Umbert A, Cervera-Carles L, Vallès M, Anglada R, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Kulisevsky J, Casals F, Clarimón J, Bosch E. Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients. *Mov Disord.* 2017 Jan;32(1):165-169.
 55. Luquin MR, Kulisevsky J, Martínez-Martin P, Mir P, Tolosa ES. Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study). *Parkinsons Dis.* 2017;2017:4047392.
 56. Colom-Cadena M, Grau-Rivera O, Planellas L, Cerquera C, Morenas E, Helgueta S, Muñoz L, Kulisevsky J, Martí MJ, Tolosa E, Clarimon J, Lleó A, Gelpi E. Regional Overlap of Pathologies in Lewy Body Disorders. *J Neuropathol Exp Neurol.* 2017 Mar 1;76(3):216-224.
 57. Fernández-Bobadilla R, Martínez-Horta S, Marín-Lahoz J, Horta-Barba A, Pagonabarraga J, Kulisevsky J. Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). *Parkinsonism Relat Disord.* 2017 Oct;43:73-77.

58. García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, Gutierrez A, Dávila JC, González-Polo RA, Fuentes JM, Mir P, Vicario C, Moratalla R. N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease. *Mov Disord.* 2017 Oct;32(10):1409-1422.
59. Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, Chaudhuri KR. Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now? *NPJ Parkinsons Dis.* 2017 Sep 5;3:28.
60. Bellosta Diago E, Pérez Pérez J, Santos Lasaosa S, Viloría Alebesque A, Martínez Horta S, Kulisevsky J, López Del Val J. Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. *Parkinsonism Relat Disord.* 2017 Nov;44:95-100.
61. Garcia-Gorro C, de Diego-Balaguer R, Martínez-Horta S, Pérez-Pérez J, Kulisevsky J, Rodríguez-Dechicha N, Vaquer I, Subira S, Calopa M, Muñoz E, Santacruz P, Ruiz-Idiago J, Mareca C, Caballol N, Camara E. Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. *Hum Brain Mapp.* 2018 Jan;39(1):54-71.
62. Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P; GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. *Parkinsonism Relat Disord.* 2017 Dec;45:13-20.
63. Pagonabarraga J, Kulisevsky J. [Safinamide from daily clinical practice: first clinical steps]. *Rev Neurol.* 2017 Nov 16;65(10):433-438.
64. Catalán MJ, Antonini A, Calopa M, Băjenaru O, de Fábregues O, Mínguez-Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevsky J. Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. *eNeurologicalSci.* 2017 Jul 2;8:44-53.
65. Prange S, Pagonabarraga J, Krack P, Kulisevsky J, Sgambato V, Tremblay L, Thobois S, Broussolle E. Historical crossroads in the conceptual delineation of apathy in Parkinson's disease. *Brain.* 2018 Feb 1;141(2):613-619.
66. Bellosta Diago E, Pérez-Pérez J, Santos Lasaosa S, Viloría Alebesque A, Martínez-Horta S, Kulisevsky J, López Del Val J. Neurocardiovascular pathology in pre-manifest and early-stage Huntington's disease. *Eur J Neurol.* 2018 Mar 14.
67. Cattaneo C, Kulisevsky J, Tubazio V, Castellani P. Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain. *Adv Ther.* 2018 Apr;35(4):515-522.
68. Martínez-Horta S, Perez-Perez J, Sampedro F, Pagonabarraga J, Horta-Barba A, Carceller-Sindreu M, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernández-León A, Carrió I, Kulisevsky J. Structural and metabolic brain correlates of apathy in Huntington's disease. *Mov Disord.* 2018 Apr 20.